Pharsight

Veltassa patents expiration

VELTASSA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8337824 VIFOR PHARMA Linear polyol stabilized polyfluoroacrylate compositions
May, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889115 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(2 months ago)

US8287847 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(2 months ago)

US8778324 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(2 months ago)

US8475780 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(2 months ago)

US10485821 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2024

(2 months ago)

US7556799 VIFOR PHARMA Ion binding polymers and uses thereof
Feb, 2025

(8 months from now)

US8216560 VIFOR PHARMA Ion binding polymers and uses thereof
Mar, 2027

(2 years from now)

US8282913 VIFOR PHARMA Ion binding polymers and uses thereof
May, 2027

(2 years from now)

US8147873 VIFOR PHARMA Methods and compositions for treatment of ion imbalances
Jun, 2028

(4 years from now)

US11123363 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia
Oct, 2033

(9 years from now)

US9925212 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia
Oct, 2033

(9 years from now)

US9492476 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia
Oct, 2033

(9 years from now)

Veltassa is owned by Vifor Pharma.

Veltassa contains Patiromer Sorbitex Calcium.

Veltassa has a total of 13 drug patents out of which 5 drug patents have expired.

Expired drug patents of Veltassa are:

  • US8889115
  • US8287847
  • US8778324
  • US8475780
  • US10485821

Veltassa was authorised for market use on 02 October, 2023.

Veltassa is available in powder;oral dosage forms.

Veltassa can be used as treatment of hyperkalemia.

Drug patent challenges can be filed against Veltassa from 22 October, 2019.

The generics of Veltassa are possible to be released after 08 October, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 02, 2026
New Strength(NS) Oct 02, 2026
New Chemical Entity Exclusivity(NCE) Oct 21, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

NCE-1 date: 22 October, 2019

Market Authorisation Date: 02 October, 2023

Treatment: Treatment of hyperkalemia

Dosage: POWDER;ORAL

How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage

VELTASSA family patents

Family Patents